vs
牛津地产（IIPR）与MEDIFAST INC（MED）财务数据对比。点击上方公司名可切换其他公司
MEDIFAST INC的季度营收约是牛津地产的1.1倍（$75.1M vs $66.7M），牛津地产同比增速更快（-13.1% vs -36.9%），过去两年牛津地产的营收复合增速更高（-6.0% vs -34.4%）
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
IIPR vs MED — 直观对比
营收规模更大
MED
是对方的1.1倍
$66.7M
营收增速更快
IIPR
高出23.8%
-36.9%
两年增速更快
IIPR
近两年复合增速
-34.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.7M | $75.1M |
| 净利润 | $31.8M | — |
| 毛利率 | — | 69.4% |
| 营业利润率 | 47.8% | -10.4% |
| 净利率 | 47.8% | — |
| 营收同比 | -13.1% | -36.9% |
| 净利润同比 | -20.4% | — |
| 每股收益（稀释后） | $1.07 | $-1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IIPRMED
| Q4 25 | $66.7M | $75.1M | ||
| Q3 25 | $64.7M | $89.4M | ||
| Q2 25 | $62.9M | $105.6M | ||
| Q1 25 | $71.7M | $115.7M | ||
| Q4 24 | $76.7M | $119.0M | ||
| Q3 24 | $76.5M | $140.2M | ||
| Q2 24 | $79.8M | $168.6M | ||
| Q1 24 | $75.5M | $174.7M |
净利润IIPRMED
| Q4 25 | $31.8M | — | ||
| Q3 25 | $29.3M | $-2.3M | ||
| Q2 25 | $26.0M | $2.5M | ||
| Q1 25 | $31.1M | $-772.0K | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.2M | $1.1M | ||
| Q2 24 | $42.0M | $-8.2M | ||
| Q1 24 | $39.4M | $8.3M |
毛利率IIPRMED
| Q4 25 | — | 69.4% | ||
| Q3 25 | — | 69.5% | ||
| Q2 25 | — | 72.6% | ||
| Q1 25 | — | 72.8% | ||
| Q4 24 | — | 74.1% | ||
| Q3 24 | — | 75.4% | ||
| Q2 24 | — | 73.2% | ||
| Q1 24 | — | 72.8% |
营业利润率IIPRMED
| Q4 25 | 47.8% | -10.4% | ||
| Q3 25 | 45.5% | -4.6% | ||
| Q2 25 | 45.9% | -1.0% | ||
| Q1 25 | 47.4% | -1.1% | ||
| Q4 24 | 54.7% | 0.6% | ||
| Q3 24 | 54.8% | 1.5% | ||
| Q2 24 | 53.1% | -4.7% | ||
| Q1 24 | 55.7% | 4.5% |
净利率IIPRMED
| Q4 25 | 47.8% | — | ||
| Q3 25 | 45.3% | -2.5% | ||
| Q2 25 | 41.4% | 2.3% | ||
| Q1 25 | 43.3% | -0.7% | ||
| Q4 24 | 52.2% | — | ||
| Q3 24 | 52.6% | 0.8% | ||
| Q2 24 | 52.6% | -4.8% | ||
| Q1 24 | 52.3% | 4.8% |
每股收益（稀释后）IIPRMED
| Q4 25 | $1.07 | $-1.64 | ||
| Q3 25 | $0.97 | $-0.21 | ||
| Q2 25 | $0.86 | $0.22 | ||
| Q1 25 | $1.03 | $-0.07 | ||
| Q4 24 | $1.35 | $0.08 | ||
| Q3 24 | $1.37 | $0.10 | ||
| Q2 24 | $1.44 | $-0.75 | ||
| Q1 24 | $1.36 | $0.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $47.6M | $167.3M |
| 总债务越低越好 | $393.7M | — |
| 股东权益账面价值 | $1.8B | $198.9M |
| 总资产 | $2.4B | $248.0M |
| 负债/权益比越低杠杆越低 | 0.21× | — |
8季度趋势，按日历期对齐
现金及短期投资IIPRMED
| Q4 25 | $47.6M | $167.3M | ||
| Q3 25 | $41.9M | $173.5M | ||
| Q2 25 | $104.9M | $162.7M | ||
| Q1 25 | $133.3M | $164.6M | ||
| Q4 24 | $151.2M | $162.3M | ||
| Q3 24 | $172.4M | $170.0M | ||
| Q2 24 | $160.9M | $163.5M | ||
| Q1 24 | $173.5M | $156.4M |
总债务IIPRMED
| Q4 25 | $393.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IIPRMED
| Q4 25 | $1.8B | $198.9M | ||
| Q3 25 | $1.9B | $214.7M | ||
| Q2 25 | $1.9B | $216.0M | ||
| Q1 25 | $1.9B | $211.0M | ||
| Q4 24 | $1.9B | $210.1M | ||
| Q3 24 | $1.9B | $207.3M | ||
| Q2 24 | $1.9B | $205.3M | ||
| Q1 24 | $2.0B | $211.0M |
总资产IIPRMED
| Q4 25 | $2.4B | $248.0M | ||
| Q3 25 | $2.3B | $268.2M | ||
| Q2 25 | $2.3B | $269.3M | ||
| Q1 25 | $2.4B | $280.0M | ||
| Q4 24 | $2.4B | $284.2M | ||
| Q3 24 | $2.4B | $291.2M | ||
| Q2 24 | $2.4B | $293.5M | ||
| Q1 24 | $2.4B | $302.8M |
负债/权益比IIPRMED
| Q4 25 | 0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.2M | $-5.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-6.6M |
| 自由现金流率自由现金流/营收 | — | -8.8% |
| 资本支出强度资本支出/营收 | — | 1.8% |
| 现金转化率经营现金流/净利润 | 6.22× | — |
| 过去12个月自由现金流最近4个季度 | — | $1.2M |
8季度趋势，按日历期对齐
经营现金流IIPRMED
| Q4 25 | $198.2M | $-5.3M | ||
| Q3 25 | $45.6M | $12.1M | ||
| Q2 25 | $48.4M | $-3.4M | ||
| Q1 25 | $54.2M | $3.4M | ||
| Q4 24 | $258.4M | $-4.9M | ||
| Q3 24 | $64.9M | $9.1M | ||
| Q2 24 | $64.2M | $13.1M | ||
| Q1 24 | $71.6M | $7.3M |
自由现金流IIPRMED
| Q4 25 | — | $-6.6M | ||
| Q3 25 | — | $10.8M | ||
| Q2 25 | — | $-4.8M | ||
| Q1 25 | — | $1.9M | ||
| Q4 24 | — | $-7.2M | ||
| Q3 24 | — | $7.7M | ||
| Q2 24 | — | $11.1M | ||
| Q1 24 | — | $5.4M |
自由现金流率IIPRMED
| Q4 25 | — | -8.8% | ||
| Q3 25 | — | 12.0% | ||
| Q2 25 | — | -4.5% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | -6.1% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 3.1% |
资本支出强度IIPRMED
| Q4 25 | — | 1.8% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.1% |
现金转化率IIPRMED
| Q4 25 | 6.22× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.86× | -1.36× | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 6.46× | — | ||
| Q3 24 | 1.61× | 8.04× | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.82× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
